Study on antifungal activity of nicotinamide and the synergistic effect of nicotinamide to itraconazole against Aspergillus fumigatus in vitro

Abstract

Abstract: Objective To investigate the effect of nicotinamide (NAE) alone or in combination with itraconazole (ITR) against Aspergillus fumigatus. Methods We investigates the antifungal effects of ITR/NAE alone and in combination against 15 isolates of Aspergillus fumigatus according to the clinical and laboratory standards institute (CLSI) M38-A2. The minimum inhibitory concentrations (MICs) and the fractional inhibitory concentration index (FICI) were used to classify drug interactions. Real-time PCR was used to test the relative expression of gene in Aspergillus fumigatus treated with nicotinamide/itraconazole. Results Niacinamide had inhibitory effect on Aspergillus fumigatus, the MICs was 12.8-25.6 mg/mL. The FICI of the drugs in combination was less than 0.5, revealing synergism between NAE and ITR. The expression of membrane protein genes and efflux pump related genes was down-regulated under nicotinamide/itraconazole. Conclusions Nicotinamide inhibited Aspergillus fumigatus and enhanced itraconazole against Aspergillus fumigatus. This effect was related to the decrease of membrane protein and efflux pump protein gene expression of Aspergillus fumigatus.

Key words: Aspergillus fumigatus, nicotinamide, itraconazole, combined therapy

CLC Number:

R379.6

CHEN Xianzhen, ZHU Xinlin, JANG Weiwei, HU Dongying, ZHANG Keming, FANG Wenjie, PAN Weihua, LIU Xiaogang, LIAO Wanqing. Study on antifungal activity of nicotinamide and the synergistic effect of nicotinamide to itraconazole against Aspergillus fumigatus in vitro[J]. Chinese Journal of Mycology, 2022, 17(2): 124-128.

References

[1] BLANCHARD E, GABRIEL F, JEANNE-LEROYER C, et al. Invasive pulmonary aspergillosis[J]. Rev Mal Respir, 2018, 35(2):171-187.
[2] 黄志伟, 张菁. 两性霉素B临床药理研究概述[J]. 中国真菌学杂志, 2021, 16(3):188-193, 210.
[3] 张诗琪, 程德云. 棘白菌素类抗真菌药物的临床应用进展[J]. 医学综述, 2020, 26(5):986-989.
[4] SNELDERS E, VAN DER LEE H A, KUIJPERS J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism[J]. PLoS Med, 2008, 5(11):e219.
[5] CHEN A C, DAMIAN D L. Nicotinamide and the skin[J]. Australas J Dermatol, 2014, 55(3):169-175.
[6] BEAL M F, HENSHAW D R, JENKINS B G, et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate[J]. Ann Neurol, 1994, 36(6):882-888.
[7] CHEN A C, MARTIN A J, CHOY B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention[J]. N Engl J Med, 2015, 373(17):1618-1626.
[8] 颜范勇, 刘冬青, 司马利锋,等. 新型烟酰胺类杀菌剂-啶酰菌胺[J]. 农药, 2008, 47(2):132-135.
[9] PRUSTY D, MEHRA P, SRIVASTAVA S, et al. Nicotinamide inhibits Plasmodium falciparum Sir2 activity in vitro and parasite growth[J]. FEMS Microbiol Lett, 2008, 282(2):266-272.
[10] SERENO D, ALEGRE A M, SILVESTRE R, et al. In vitro antileishmanial activity of nicotinamide[J]. Antimicrob Agents Chemother, 2005, 49(2):808-812.
[11] TCHERNIUK S O, CHESNOKOVA O, OLEINIKOV I V, et al. Nicotinamide inhibits the growth of P. falciparum and enhances the antimalarial effect of artemisinin, chloroquine and pyrimethamine[J]. Mol Biochem Parasitol, 2017, 216(1):14-20.
[12] UNCITI-BROCETA J D, MACEIRA J, MORALES S, et al. Nicotinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes[J]. J Biol Chem, 2013, 288(15):10548-10557.
[13] XING X, LIAO Z, TAN F, et al. Effect of nicotinamide against Candida albicans[J]. Front Microbiol, 2019, 10(1):595.
[14] WURTELE H, TSAO S, LEPINE G, et al. Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy[J]. Nat Med, 2010, 16(7):774-780.
[15] JOHN H R. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition[J]. Clin Lab Stand Inst, 2008, 28(16):1-35.
[16] 张馨予, 潘开素, 罗宏, 等. 中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究[J]. 中国真菌学杂志, 2021, 16(3):176-181.
[17] LI S X, SONG Y J, JIANG L, et al. Synergistic effects of tetrandrine with posaconazole against Aspergillus fumigatus[J]. Microb Drug Resist, 2017, 23(6):674-681.
[18] BONGOMIN F, GAGO S, OLADELE R O, et al. Global and multi-national prevalence of fungal diseases-estimate precision[J]. J Fungi (Basel), 2017, 3(4):57.
[19] DAGENAIS T R, KELLER N P. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis[J]. Clin Microbiol Rev, 2009, 22(3):447-465.
[20] SONG S B, PARK J S, CHUNG G J, et al. Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide[J]. Metabolomics, 2019, 15(10):137.
[21] MURRAY M F. Nicotinamide:an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus[J]. Clin Infect Dis, 2003, 36(4):453-460.
[22] DENNING D W, VENKATESWARLU K, OAKLEY K L, et al. Itraconazole resistance in Aspergillus fumigatus[J]. Antimicrob Agents Chemother, 1997, 41(6):1364-1368.
[23] 吴锐, 刁文琦, 宋延君, 等. 以棋盘法测定汉防己甲素与伊曲康唑的体外联合抗烟曲霉作用[J]. 中国人兽共患病学报, 2013, 29(8):748-752.
[24] PEREZ-CANTERO A, LOPEZ-FERNANDEZ L, GUARRO J, et al. Azole resistance mechanisms in Aspergillus:update and recent advances[J]. Int J Antimicrob Agents, 2020, 55(1):105807.
[25] 郝小康, 王宇鹤, 徐世林,等. 土槿乙酸与氟康唑联合抗白念珠菌作用的研究[J]. 中国真菌学杂志, 2021, 16(4):262.
[26] 南春辉. 麦角甾醇的研究进展[J]. 中国新技术新产品, 2009, (10):6.
[27] FRACZEK M G, BROMLEY M, BUIED A, et al. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus[J]. J Antimicrob Chemother, 2013, 68(7):1486-1496.